Realising the potential of a safe and protective universal vaccine for African horse sickness disease

实现非洲马瘟安全且具有保护性的通用疫苗的潜力

• 批准号: BB/R005567/1
• 负责人: Polly Roy
• 金额: $ 30.24万
• 依托单位: London School of Hygiene & Tropical Medicine
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FR005567%2F1
• 关键词: Realising; potential; safe; protective; universal

African horse sickness is a devastating viral disease of horses with a ~90% mortality rate. AHSV and Bluetongue Virus, BTV, that affects livestock, are closely related and spread by the same Culicoides vectors, prevalent in UK & Europe. Currently available vaccines against AHSV are neither safe nor effective and a safe vaccine that protects against all AHSV serotypes is desirable. Enabled by BBSRC funding we have designed novel vaccine candidates for all nine AHSV serotypes which are strictly replication-deficient in normal cells or animal hosts and demonstrated their suitability in ponies. To investigate their potential for commercialisation, we will investigate the duration of protection in ponies; develop a unique universal vaccine for all serotypes; define the immune response and those that are responsible for cross-protection; and develop a DIVA vaccine strain. Our data will support a broadly protective vaccine with easy production and good shelf life for protection against AHSV

非洲马瘟是一种毁灭性的病毒性疾病，死亡率约为90%。AHSV和影响牲畜的蓝舌病病毒BTV密切相关，并通过相同的库蠓媒介传播，在英国和欧洲流行。目前可获得的针对AHSV的疫苗既不安全也不有效，并且需要保护免受所有AHSV血清型的安全疫苗。在BBSRC的资助下，我们为所有9种AHSV血清型设计了新的候选疫苗，这些血清型在正常细胞或动物宿主中严格复制缺陷，并证明了它们在小马中的适用性。为了研究它们的商业化潜力，我们将研究小马的保护持续时间;开发一种适用于所有血清型的独特通用疫苗;定义免疫应答和负责交叉保护的免疫应答;并开发DIVA疫苗株。我们的数据将支持广泛的保护性疫苗，易于生产和良好的保质期，以保护对AHSV